Post-earnings recap
Reported
Tue, Aug 6, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Haemonetics Corp's strong EPS performance, surpassing expectations by over 22%, led to a significant stock increase of 12.02%. Investors reacted positively to the company's ability to deliver better-than-expected earnings, despite the lack of revenue data and future guidance. The management's focus on operational improvements suggests potential for continued growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.81 | N/A | +22.42% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook regarding their EPS results, emphasizing their commitment to improving operations. However, they did not provide specific guidance for the future.
Management expressed satisfaction with the EPS performance.
They highlighted ongoing efforts to enhance operational efficiency.